C-XG0JMoonwalk Bio
adipose biology, epigenetic engineering, siRNA
editingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-XG0J
C-XG0JC-XG0Jadipose biology, epigenetic engineering, siRNA
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Moonwalk Biosciences states that disease can be better treated by deeply profiling, understanding, and targeting the epigenetic code to return cells to a healthy state. The company presents epigenomic biology as a causal layer that can reveal actionable therapeutic targets and guide the choice of modality, including small molecules, oligonucleotide therapeutics, and direct editing strategies, with an initial focus on cardiometabolic and obesity-related diseases.
SourceMoonwalk Biosciences states that it is pioneering novel therapeutics in adipose biology and tissue, and that this work is driven by deep genetic and epigenetic insights. The visible text presents the company as focused on using those biological insights to develop new treatments in the adipose and cardiometabolic space.
SourceMoonwalk Biosciences states that deeply profiling, targeting, and engineering the epigenetic code can reprogram diseased cells back to a healthy state, creating a fundamentally new way to discover and develop therapies for complex diseases. The company presents the epigenome as a new therapeutic target space and argues that combining AI-based epigenetic target prediction with read-and-write epigenetic engineering tools can enable potentially curative treatments that address disease at its root cause.
Source